ORIC Pharmaceuticals Inc (NAS:ORIC)

$ 9.15 -0.02 (-0.22%) Market Cap: 616.91 Mil Enterprise Value: 301.56 Mil PE Ratio: 0 PB Ratio: 1.88 GF Score: 40/100

Oric Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 21, 2024
Oric Pharmaceuticals Inc at Guggenheim Healthcare Talks Biotechnology Conference Transcript
Feb 07, 2024
Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Oric Pharmaceuticals Inc ASH 2023 Business Update Call Transcript
Dec 11, 2023
Oric Pharmaceuticals Inc Business Update ESMO Call Transcript
Oct 21, 2023
Oric Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Sep 06, 2023
Oric Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Oric Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 22, 2023
Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Merus NV and ORIC Pharmaceuticals Inc at Citi BioPharma Conference Transcript
Sep 08, 2022
Q4 2021 Oric Pharmaceuticals Inc Earnings Call Transcript
Mar 21, 2022

$6.68 (-1.47%)

Earnings
Oric Pharmaceuticals Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
Feb 10, 2022
Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Oric Pharmaceuticals Inc to Discuss CD73 Inhibitor Program in Multiple Myeloma Transcript
Dec 13, 2021
Oric Pharmaceuticals Inc at AACR-NCI-EORTC Virtual International Conference Transcript
Oct 07, 2021
Oric Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 10, 2021
Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript
Jun 02, 2021
Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021

Oric Pharmaceuticals Inc To Review Initial Data ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-Paclitaxel Transcript

Jun 02, 2021 / 09:00PM GMT

Release Date Price: $21.5 (-6.68%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the ORIC conference call to review the initial data being presented at ASCO from the Phase Ib study of ORIC-101 in combination with nab-paclitaxel. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to today's first speaker, ORIC's CFO, Dominic Piscitelli. Thank you. Please go ahead, sir.

Dominic G. Piscitelli

ORIC Pharmaceuticals, Inc. - CFO

Good afternoon, and welcome to the ORIC Pharmaceuticals Business Update ASCO 2021 Conference Call. Following the market close today, we issued a press release highlighting the initial clinical data from our ongoing Phase Ib trial of ORIC-101 in combination with nab-paclitaxel in advanced solid tumors. You may find the press release posted on the Investor page of oricpharma.com. We are dialed in from different locations today, so please bear with us if we have any technical difficulties.

Before we begin, starting on Slide 2, during this

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.